Targeting Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9): from Bench to Bedside

Overview

Journal Signal Transduct Target Ther

Specialties Cell Biology
Pharmacology

Date 2024 Jan 7

PMID 38185721

Authors

Xuhui Bao

Yongjun Liang

Hanman Chang

Tianji Cai

Baijie Feng

Konstantin Gordon

Yuekun Zhu

Hailian Shi

Yundong He

Liyi Xie

Affiliations

Soon will be listed here.

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its related cardiovascular diseases (CVD). This comprehensive review delineates the intricate roles and wide-ranging implications of PCSK9, extending beyond CVD to emphasize its significance in diverse physiological and pathological states, including liver diseases, infectious diseases, autoimmune disorders, and notably, cancer. Our exploration offers insights into the interaction between PCSK9 and low-density lipoprotein receptors (LDLRs), elucidating its substantial impact on cholesterol homeostasis and cardiovascular health. It also details the evolution of PCSK9-targeted therapies, translating foundational bench discoveries into bedside applications for optimized patient care. The advent and clinical approval of innovative PCSK9 inhibitory therapies (PCSK9-iTs), including three monoclonal antibodies (Evolocumab, Alirocumab, and Tafolecimab) and one small interfering RNA (siRNA, Inclisiran), have marked a significant breakthrough in cardiovascular medicine. These therapies have demonstrated unparalleled efficacy in mitigating hypercholesterolemia, reducing cardiovascular risks, and have showcased profound value in clinical applications, offering novel therapeutic avenues and a promising future in personalized medicine for cardiovascular disorders. Furthermore, emerging research, inclusive of our findings, unveils PCSK9's potential role as a pivotal indicator for cancer prognosis and its prospective application as a transformative target for cancer treatment. This review also highlights PCSK9's aberrant expression in various cancer forms, its association with cancer prognosis, and its crucial roles in carcinogenesis and cancer immunity. In conclusion, this synthesized review integrates existing knowledge and novel insights on PCSK9, providing a holistic perspective on its transformative impact in reshaping therapeutic paradigms across various disorders. It emphasizes the clinical value and effect of PCSK9-iT, underscoring its potential in advancing the landscape of biomedical research and its capabilities in heralding new eras in personalized medicine.

Citing Articles

Causal relationship between drug target genes of LDL-cholesterol and coronary artery disease: drug target Mendelian randomization study.

Jee Y, Shin J, Ryu M, Song T Lipids Health Dis. 2025; 24(1):92.

PMID: 40082904 PMC: 11905656. DOI: 10.1186/s12944-025-02502-z.

Advances in Oral Biomacromolecule Therapies for Metabolic Diseases.

Jiao Q, Huang Y, He J, Xu Y Pharmaceutics. 2025; 17(2).

PMID: 40006605 PMC: 11859201. DOI: 10.3390/pharmaceutics17020238.

Recent Advances in Indocyanine Green-Based Probes for Second Near-Infrared Fluorescence Imaging and Therapy.

Hu D, Zha M, Zheng H, Gao D, Sheng Z Research (Wash D C). 2025; 8():0583.

PMID: 39830366 PMC: 11739436. DOI: 10.34133/research.0583.

CD36 in liver diseases.

Liu Y, Yin W Hepatol Commun. 2025; 9(1.

PMID: 39774047 PMC: 11717518. DOI: 10.1097/HC9.0000000000000623.

PCSK9 in T-cell function and the immune response.

Wang Y, Fang X, Liu J, Lv X, Lu K, Lu Y Biomark Res. 2024; 12(1):163.

PMID: 39736777 PMC: 11687167. DOI: 10.1186/s40364-024-00712-8.

References

Merleev A, Ji-Xu A, Toussi A, Tsoi L, Le S, Luxardi G . Proprotein convertase subtilisin/kexin type 9 is a psoriasis-susceptibility locus that is negatively related to IL36G. JCI Insight. 2022; 7(16). PMC: 9462487. DOI: 10.1172/jci.insight.141193. View

Udalova I, Mantovani A, Feldmann M . Macrophage heterogeneity in the context of rheumatoid arthritis. Nat Rev Rheumatol. 2016; 12(8):472-85. DOI: 10.1038/nrrheum.2016.91. View

Ray K, Wright R, Kallend D, Koenig W, Leiter L, Raal F . Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020; 382(16):1507-1519. DOI: 10.1056/NEJMoa1912387. View

Grefhorst A, McNutt M, Lagace T, Horton J . Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res. 2008; 49(6):1303-11. PMC: 2386900. DOI: 10.1194/jlr.M800027-JLR200. View

Zhang X, Qin J, Cheng X, Shen L, Zhao Y, Yuan Y . In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020; 32(2):176-187.e4. PMC: 7311917. DOI: 10.1016/j.cmet.2020.06.015. View

Cammisotto V, Baratta F, Castellani V, Bartimoccia S, Nocella C, DErasmo L . Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. Int J Mol Sci. 2021; 22(13). PMC: 8267646. DOI: 10.3390/ijms22137193. View

Cui Y, Zhao X, Qi L, Li X, Huang Z, Yang G . A Potential Long-Acting LDL-Cholesterol-Lowering PCSK9 Monoclonal Antibody: Randomized, Placebo-Controlled Phase 1 Studies. JACC Asia. 2022; 1(3):411-415. PMC: 9627834. DOI: 10.1016/j.jacasi.2021.09.002. View

Chen Y, Troutt J, Konrad R . PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day. Lipids. 2014; 49(5):445-55. DOI: 10.1007/s11745-014-3895-6. View

Adorni M, Zimetti F, Lupo M, Ruscica M, Ferri N . Naturally Occurring PCSK9 Inhibitors. Nutrients. 2020; 12(5). PMC: 7284437. DOI: 10.3390/nu12051440. View

10.

Seidah N . The Elusive Inhibitory Function of the Acidic N-Terminal Segment of the Prodomain of PCSK9: The Plot Thickens. J Mol Biol. 2019; 431(5):904-907. DOI: 10.1016/j.jmb.2019.01.015. View

11.

McGehee O, Ebrahim H, Rad A, Abdelwahed K, Mudhish E, King J . Towards Developing Novel Prostate Cancer Recurrence Suppressors: Acute Toxicity of Pseurotin A, an Orally Active PCSK9 Axis-Targeting Small-Molecule in Swiss Albino Mice. Molecules. 2023; 28(3). PMC: 9922019. DOI: 10.3390/molecules28031460. View

12.

Lebeau P, Byun J, Platko K, MacDonald M, Poon S, Faiyaz M . Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing PCSK9 expression in mice. J Biol Chem. 2019; 294(23):9037-9047. PMC: 6556582. DOI: 10.1074/jbc.RA119.008094. View

13.

Ding Q, Strong A, Patel K, Ng S, Gosis B, Regan S . Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. 2014; 115(5):488-92. PMC: 4134749. DOI: 10.1161/CIRCRESAHA.115.304351. View

14.

Luo X, Xu J, Wang Z, Wang X, Zhu Q, Zhao J . Bioinformatics Identification of Key Genes for the Development and Prognosis of Lung Adenocarcinoma. Inquiry. 2022; 59:469580221096259. PMC: 9158403. DOI: 10.1177/00469580221096259. View

15.

Lai Q, Giralt A, Le May C, Zhang L, Cariou B, Denechaud P . E2F1 inhibits circulating cholesterol clearance by regulating Pcsk9 expression in the liver. JCI Insight. 2017; 2(10). PMC: 5436545. DOI: 10.1172/jci.insight.89729. View

16.

Cariou B, Ouguerram K, Zair Y, Guerois R, Langhi C, Kourimate S . PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 2009; 29(12):2191-7. DOI: 10.1161/ATVBAHA.109.194191. View

17.

Iskandar S, Bowers A . mRNA Display Reaches for the Clinic with New PCSK9 Inhibitor. ACS Med Chem Lett. 2022; 13(9):1379-1383. PMC: 9465826. DOI: 10.1021/acsmedchemlett.2c00319. View

18.

Sun Y, Zhang H, Meng J, Guo F, Ren D, Wu H . S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway. Cell Rep. 2022; 40(7):111194. DOI: 10.1016/j.celrep.2022.111194. View

19.

Peyot M, Roubtsova A, Lussier R, Chamberland A, Essalmani R, Murthy Madiraju S . Substantial PCSK9 inactivation in β-cells does not modify glucose homeostasis or insulin secretion in mice. Biochim Biophys Acta Mol Cell Biol Lipids. 2021; 1866(8):158968. DOI: 10.1016/j.bbalip.2021.158968. View

20.

Iacocca M, Wang J, Sarkar S, Dron J, Lagace T, McIntyre A . Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia. Can J Cardiol. 2018; 34(10):1316-1324. DOI: 10.1016/j.cjca.2018.07.479. View